The patent is not expiring Pfizer's $6 billion star drug price slash!

Source: Pfizer | Recently, Pfizer announced that its company's breast cancer star drug, Paisley (commodity name: Aibo New ®), has been priced down by 54%, while Pfizer has made adjustments to the "Charity Freshman-Patient Assistance Program" to phase out previous charitable grants for low- and low-income patients.
is understood to be the first major price cut by Aiboxin since it was approved for listing in China in 2018.
Pfizer Pybersili hanging network price adjustment details table data and information sources: Shandong Province pharmaceutical centralized procurement platform Aibo new hanging network information Aiboxin, the world's first cell cycle protein-dependent kinase (CDK) 4/6 inhibition In 2013, the FDA approved Aibo New ® as a breakthrough new drug for the treatment of advanced breast cancer, and in 2015 the FDA approved Aibo New ® as a rapid approval process for the treatment of advanced breast cancer.
Based on this breakthrough, the National Comprehensive Cancer Network (NCCN) guidelines recommend Aibo New ® Joint Aromatase Inhibitor as a first-line treatment for HR-/HER2-advanced or metastasis breast cancer;
6 billion U.S. dollars, the World Health Organization's International Agency for Research on Cancer (IARC) released the latest global cancer burden data for 2020 in early January, including 2.26 million new cases of breast cancer worldwide, surpassing 2.2 million cases of lung cancer, which overtook lung cancer as the world's largest cancer, while breast cancer was one of the top 10 cancer deaths among women in China in 2020, with 120,000 cases.
market is huge.
There is no doubt that in the face of huge market prospects, CDK4/6 has become a hot target for major companies in recent years, according to pharmaceutical data, the FDA has approved a total of three CDK4/6 antidote drugs for breast cancer treatment, namely Pfizer's Ibersili, Novarma's Rebosini, Lilly's Abemaciclib.
2019, global CDK4/6 inhibitor sales reached $6,021 million, with Pfizer's global sales of $4,961 million, up 30.54 percent year-on-year, or about 82 percent of the overall CDK4/6 inhibitor market share, according to public data from the FDA-approved CDK4/6 Inhibitor Details Table.
Hengrui innovation and research and development is the fastest, Qilu first imitation listed approved according to incomplete statistics, so far there are more than 20 CDK4/6 inhibitor new drugs in the study, of which 11 drugs belong to China's first class of innovative drugs, Hengrui pharmaceutical research and development progress is the fastest, has been to clinical phase 3 trials.
details of the progress of cdK4/6 inhibitor innovation drug research and development in China Note: This table is incomplete statistics, welcome to add.
it is worth mentioning that in December 2020, Qilu Pharmaceutical's first generic drugs, the 'Pybersili Capsule' and Lilly's 'Abemaciclib' tablets, were approved for listing by China's State Drug Administration.
To this point, China's CDK4/6 inhibitor market has also formed a "three-legged stand-up" trend, Pfizer's Aboxin will no longer be a single big, Qilu Pharmaceuticals and Lilly will certainly split China's breast cancer drug this fertile market cake.
In addition, Haussen Pharmaceuticals and Nanjing Sonic Pharmaceuticals' application for the listing of pyridoxili capsule generics has been accepted by CDE, Haizheng, Osaikang, Wanbang Biopharmaceuticals and other pharmaceutical industries, most of which have completed BE trials.
the CDK4/6 inhibitors will become increasingly competitive.
Pfizer's intention to halve the price in advance, if the details of the patent are not due for the filing of a generic generic drug in the Pypaxili capsule? The earliest expiration date for Pfizer's original Psili patent was January 2023, according to The Pharmaceuticals Patent Pass.
it is well known that, in order to encourage innovative research and development, the original research and innovation drugs to give a certain period of market protection, which means that the original research drug patents have not expired before the generic drugs can not be listed.
Now Pfizer's Abo new has 2 years before the patent expires, but choose to reduce the price by half, the price reduction time just selected Qilu first generic drug approved for listing, with the domestic introduction of Lilly abemaciclib listed for import - the domestic will usher in the second CDK4/6 inhibitor drug after the time period, behind the deep thought is worth thinking about.
2019, although Aibo new into the Health Insurance Bureau's proposed 128 drug catalog, but because the domestic market at that time the product Pfizer is a large, no competition exists, Pfizer did not choose to enter health insurance.
Pfizer still doesn't have the option to go into health care in the 2020 health-care negotiations, just as there is little competition for its products that are not yet on the market or are about to go public in China.
now, Pfizer has opted for an early price cut before the patent expires at the market level.
Under normal logic, the price of generic drugs is far lower than the original drug, no doubt, Qilu pharmaceutical first generic drug persili capsule market prices should also be much lower than Aiboxin, while similar products Lilly Pharmaceuticals abemaciclib imports were approved, Pfizer abandoned access to the health insurance catalog In addition, in the current national medical reform system in-depth promotion, rapid tightening of bidding policy and other series of policy combinations, foreign-funded enterprises "super-national treatment" pricing preferential policies gradually eliminated, in the face of heavy pressure, Pfizer chose to cut prices first, stabilize the market leading position, the first advantage will be the market further income under the arm.
addition, Pfizer and Novartis' two competing CDK4/6 inhibitors compete on the indications, but it's worth noting that Abesili is also good for early-stage breast cancer patients.
in May and October 2020, Pfizer announced the clinical failure of CDK4/6 complementary therapy in the Hr-/HER2-Early Breast Cancer Relapse of the Persimbosili capsule;
CDK4/6 inhibitor anti-breast cancer treatment market is "smoke and smoke", the competitive situation is becoming more and more intense ...